Entity

Time filter

Source Type


Mickleborough T.D.,Human Performance and Exercise Biochemistry Laboratory | Sinex J.A.,Human Performance and Exercise Biochemistry Laboratory | Platt D.,Human Performance and Exercise Biochemistry Laboratory | Chapman R.F.,Human Performance and Exercise Biochemistry Laboratory | Hirt M.,Human Performance and Exercise Biochemistry Laboratory
Journal of the International Society of Sports Nutrition | Year: 2015

Background: The purpose of the present study was to evaluate the effects of PCSO-524®, a marine oil lipid and n-3 LC PUFA blend, derived from New Zealand green- lipped mussel (Perna canaliculus), on markers of muscle damage and inflammation following muscle damaging exercise in untrained men. Methods: Thirty two untrained male subjects were randomly assigned to consume 1200 mg/d of PCSO- 524® (a green-lipped mussel oil blend) or placebo for 26 d prior to muscle damaging exercise (downhill running), and continued for 96 h following the muscle damaging exercise bout. Blood markers of muscle damage (skeletal muscle slow troponin I, sTnI; myoglobin, Mb; creatine kinase, CK), and inflammation (tumor necrosis factor, TNF-α), and functional measures of muscle damage (delayed onset muscle soreness, DOMS; pressure pain threshold, PPT; knee extensor joint range of motion, ROM; isometric torque, MVC) were assessed pre- supplementation (baseline), and multiple time points post-supplementation (before and after muscle damaging exercise). At baseline and 24 h following muscle damaging exercise peripheral fatigue was assessed via changes in potentiated quadriceps twitch force (δQtw,pot) from pre- to post-exhaustive cycling ergometer test in response to supra-maximal femoral nerve stimulation. Results: Compared to placebo, supplementation with the green-lipped mussel oil blend significantly attenuated (p<0.05) sTnI and TNF-α at 2, 24, 48, 72 and 96 h., Mb at 24, 48, 72, 96 h., and CK-MM at all-time points following muscle damaging exercise, significantly reduced (p<0.05) DOMS at 72 and 96 h post-muscle damaging exercise, and resulted in significantly less strength loss (MVC) and provided a protective effect against joint ROM loss at 96 h post- muscle damaging exercise. At 24 h after muscle damaging exercise perceived pain was significantly greater (p<0.05) compared to baseline in the placebo group only. Following muscle damaging exercise ΔQtw,pot was significantly less (p<0.05) on the green-lipped mussel oil blend compared to placebo. Conclusion: Supplementation with a marine oil lipid and n-3 LC PUFA blend (PCSO-524®), derived from the New Zealand green lipped mussel, may represent a useful therapeutic agent for attenuating muscle damage and inflammation following muscle damaging exercise. © Mickleborough et al. Source


Mickleborough T.D.,Human Performance and Exercise Biochemistry Laboratory | Vaughn C.L.,Human Performance and Exercise Biochemistry Laboratory | Shei R.-J.,Human Performance and Exercise Biochemistry Laboratory | Davis E.M.,Human Performance and Exercise Biochemistry Laboratory | Wilhite D.P.,Human Performance and Exercise Biochemistry Laboratory
Respiratory Medicine | Year: 2013

Purpose Evaluate the effect of the marine lipid fraction of the New Zealand green-lipped mussel (Perna canaliculus) PCSO-524™ (Lyprinol ®/Omega XL®), rich in omega-3 fatty acids, on airway inflammation and the bronchoconstrictor response to eucapnic voluntary hyperpnea (EVH) in asthmatics. Methods Twenty asthmatic subjects, with documented HIB, participated in a placebo controlled double-blind randomized crossover trial. Subjects entered the study on their usual diet and were then placed on 3 weeks of PCSO-524™ or placebo supplementation, followed by a 2 week washout period, before crossing over to the alternative diet. Pre- and post-eucapnic voluntary hyperpnea (EVH) pulmonary function, fraction of exhaled nitric oxide (FENO), asthma symptom scores, medication use, exhaled breath condensate (EBC) pH, cysteinyl leukotrienes (cyst-LT), 8-isoprostane and urinary 9α, 11β-prostaglandin (PG)F2 and Clara (CC16) protein concentrations were assessed at the beginning of the trial and at the end of each treatment period. Results The PCSO-524™ diet significantly reduced (p < 0.05) the maximum fall in post-EVH FEV1 (-8.4 ± 3.2%) compared to usual (-19.3 ± 5.4%) and placebo diet (-22.5 ± 13.7%). Pre- and post- EVH EBC cyst-LT and 8-isoprostane, and urinary 9α, 11β-PGF2 and CC16 concentrations were significantly reduced (p < 0.05) on the PCSO-524™ diet compared to the usual and placebo diet. EBC pH and asthma symptom scores were significantly improved (p < 0.05) and rescue medication use significantly reduced (p < 0.05) on the PCSO-524™ diet compared to the usual and placebo diet. Conclusion PCSO-524™ (Lyprinol®/Omega XL®) may have beneficial effects in HIB and asthma by serving as a pro-resolving agonist and/or inflammatory antagonist. © 2012 Elsevier Ltd. All rights reserved. Source

Discover hidden collaborations